Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2012

View Archived Issues

New 5-lipoxygenase inhibitors claimed by Ranbaxy Laboratories

AZD-4694 PET detects Alzheimer's disease pathology in patients

Cancer vaccine shows activity in phase I/II trial

Kampo medicine reduces oxaliplatin-induced peripheral neuropathy in patients with cancer

Novel approach yields first small-molecule ligand for wild-type p53 DNA-binding domain

Panobinostat trial in colorectal cancer yields mixed results

Vanderbilt University patents new indoles

New insulin secretagogues prepared in Japan

Phase II trial investigates GS-7340 as part of a new treatment regimen

Amorcyte kicks off enrollment in phase II AMR-001 study

AC Immune and University of Basel enter research agreement

Sanwa Kagaku Kenkyusho presents novel glucokinase activators

Novel somatostatin receptor ligands reported

FDA approves gel for actinic keratosis

Incyte synthesizes novel PI3K-delta inhibitors

FDA clears updated Vytorin label

Bilastine launched in Brazil

New protease-activated PAR1 receptor antagonists disclosed

FDA expands Keppra indication

Neurocrine Biosciences product gets FDA fast track status

Spectrum Pharmaceuticals enters licensing agreement for Zevalin

CHMP issues opinion on Remicade for ulcerative colitis in children

Phase III afatinib trials begin in head and neck cancer

Targovax secures funding for cancer vaccine research

Initial phase III data show promise for tasimelteon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...